OmniAb, Inc. (OABI) vs Zevra Therapeutics, Inc. (ZVRA)
OmniAb, Inc. and Zevra Therapeutics, Inc. are both Biotechnology companies. OmniAb, Inc. and Zevra Therapeutics, Inc. are of similar size ($697.9M and $668.7M). OmniAb, Inc. has negative trailing earnings, so its P/E is not meaningful; Zevra Therapeutics, Inc. trades at 11.6×. Zevra Therapeutics, Inc. grew revenue faster over the last twelve months: 119.4% against 67.0%. Zevra Therapeutics, Inc. has the higher net margin (42.3% vs −115.1%) and the higher return on invested capital (0.00% vs −14.5%). Across the 16 metrics below, Zevra Therapeutics, Inc. leads on 13 and OmniAb, Inc. on 3.
Valuation
Profitability
| Metric | OABI | ZVRA | Biotechnology median |
|---|---|---|---|
| Gross margin | 98.28% | 95.46% | 65.16% |
| Operating margin | (125.78%) | 60.54% | 0.00% |
| Net margin | (115.12%) | 42.25% | 0.00% |
| Free cash flow margin | (47.17%) | 24.30% | 0.00% |
| Return on equity | (16.95%) | 34.33% | (57.72%) |
| Return on assets | (15.11%) | 20.57% | (49.22%) |
| Return on invested capital | (14.52%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack